Lipocine Announces Presentations on TLANDO™ at AUA Virtual Experience 2020
SALT LAKE CITY, May 15, 2020 /PRNewswire/ — Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data for lead candidate TLANDO™ will be presented at the American Urological Association…
Comments Off on Lipocine Announces Presentations on TLANDO™ at AUA Virtual Experience 2020